Amylyx Pharmaceuticals Future Growth

Future criteria checks 0/6

Amylyx Pharmaceuticals's revenue is forecast to decline at 68.6% per annum while its annual earnings are expected to grow at 36.5% per year. EPS is expected to grow by 33.3% per annum.

Key information

36.5%

Earnings growth rate

33.3%

EPS growth rate

Pharmaceuticals earnings growth	23.8%
Revenue growth rate	-68.6%
Future return on equity	n/a
Analyst coverage	Good
Last updated	18 Nov 2024

Recent future growth updates

Recent updates

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Nov 04

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates

Jul 18

Earnings and Revenue Growth Forecasts

NasdaqGS:AMLX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	0	-84	N/A	N/A	5
12/31/2025	N/A	-105	N/A	N/A	6
12/31/2024	88	-298	N/A	N/A	5
9/30/2024	196	-259	-132	-95	N/A
6/30/2024	299	-166	-60	-59	N/A
3/31/2024	398	-71	15	17	N/A
12/31/2023	381	49	11	12	N/A
9/30/2023	294	2	-53	-51	N/A
6/30/2023	192	-73	-91	-89	N/A
3/31/2023	94	-149	-147	-144	N/A
12/31/2022	22	-198	-182	-180	N/A
9/30/2022	0	-184	-161	-158	N/A
6/30/2022	0	-153	-138	-136	N/A
3/31/2022	0	-121	-103	-103	N/A
12/31/2021	0	-88	-75	-75	N/A
9/30/2021	1	-68	-56	-55	N/A
12/31/2020	1	-42	-37	-37	N/A
12/31/2019	1	-14	-11	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMLX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AMLX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AMLX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AMLX's revenue is expected to decline over the next 3 years (-68.6% per year).

High Growth Revenue: AMLX's revenue is forecast to decline over the next 3 years (-68.6% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AMLX's Return on Equity is forecast to be high in 3 years time

Amylyx Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 22%

Price target increased by 25% to US$5.33

Consensus EPS estimates fall by 30%

Consensus revenue estimates fall by 45%

Consensus revenue estimates fall by 19%

Consensus EPS estimates fall by 54%

Recent updates

Consensus EPS estimates fall by 22%

Co-Founder exercised options to buy US$427k worth of stock.

Third quarter 2024 earnings released: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 25% to US$5.33

Amylyx Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2 Helios Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Amylyx Pharmaceuticals, Inc. to Host Virtual Webcast to Discuss Topline Results from Phase 2 Helios Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Co-Founder recently sold US$59k worth of stock

Co-Founder exercised options to buy US$99k worth of stock.

Chief Financial Officer recently bought US$101k worth of stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Independent Chairman of the Board recently bought US$220k worth of stock

Consensus EPS estimates fall by 30%

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of Amx0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’S Disease Pathology and Neurodegeneration

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Amylyx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Index

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

New minor risk - Profitability

Investor sentiment improves as stock rises 15%

Amylyx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Amylyx Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Investor sentiment deteriorates as stock falls 20%

Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Consensus revenue estimates fall by 45%

Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market

New major risk - Revenue and earnings growth

Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors

Investor sentiment deteriorates as stock falls 83%

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Rosen Law Firm Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Consensus revenue estimates fall by 19%

An ALS Drug Fails Again

Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

Investor sentiment improves as stock rises 28%

Consensus EPS estimates fall by 54%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Amylyx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 Orion Study of Amx0035 in Progressive Supranuclear Palsy (Psp)

Amylyx Pharmaceuticals, Inc. Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian as Chief Medical Officer

Price target decreased by 17% to US$39.40

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

New minor risk - Share price stability

Amylyx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium

Amylyx Pharmaceuticals, Inc. Receives Negative Chmp Opinion on Its Marketing Authorisation Application for Amx0035 for the Treatment of Als in the European Union Following Re-Examination Process

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing Centaur to Historical Clinical Trial Control

Amylyx Pharmaceuticals Provides Update on Acces Compassionnel for AMX0035 in France

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Amylyx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Quebec for the Public Reimbursement of Albriza

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Ontario for Public Reimbursement of ALBRIOZA Through Ontario Drug Benefit Program

Amylyx Pharmaceuticals, Inc. Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

Amylyx Pharmaceuticals, Inc. Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

Insider notifies of intention to sell stock

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Forecast breakeven date moved forward to 2023